Key result
High-dose furosemide plus hypertonic saline increases diuresis and reduces BNP and readmissions versus furosemide alone.
Why the study?
The study was designed to evaluate the effect of combining high-dose furosemide with small-volume hypertonic saline solution versus high-dose furosemide alone on BNP plasma levels and hydration state in refractory CHF.
Does the combination of high-dose furosemide and hypertonic saline solution improve BNP levels and hydration state in patients with refractory congestive heart failure compared to high-dose furosemide alone?
RCT (n=94)
Double-blind
Does the combination of high-dose furosemide and hypertonic saline solution improve BNP levels and hydration state in patients with refractory congestive heart failure compared to high-dose furosemide alone?
p-value: p=<0.05
The addition of hypertonic saline to high-dose intravenous furosemide in refractory heart failure improves diuresis, reduces BNP levels faster, and decreases hospital length of stay and 30-day readmissions.
OBJECTIVES: The aim of this study was to evaluate the effect of a new treatment for refractory congestive heart failure (CHF) on brain natriuretic peptide (BNP) plasma levels and hydration station. BACKGROUND: The study was aimed at evaluating the effects of the combination of high-dose furosemide and small-volume hypertonic saline solution (HSS) in refractory CHF patients. METHODS: A total of 94 patients (34 women/60 men) with refractory CHF (age 55 to 80 years) were enrolled. They had to have an ejection fraction <35%, serum creatinine <2 mg/dl, blood urea nitrogen <60 mg/dl, a reduced urinary volume, and a low natriuresis (<500 ml/24 h and <60 mEq/24 h, respectively). Patients were divided (double-blind) into two groups: group 1 (18 women/30 men) received an intravenous furosemide (500 to 1,000 mg) plus HSS twice a day in 30 min. Group 2 (16 women/30 men) received an intravenous bolus of furosemide (500 to 1,000 mg/twice a day) alone, for four to six days. At entry, body weight, blood pressure, heart rate, and laboratory parameters were checked during hospitalization; BNP levels were measured on admission, 6 and 30 days after discharge, while on admission and 6 days after, impedance plethysmography was performed. The HSS group received 120 mmol of Na intake versus 80 mmol in non-HSS group. Fluid intake of 1,000 was given to both groups. RESULTS: The groups were similar for clinical characteristics. A significant increase in daily diuresis and natriuresis was observed in HSS group, p < 0.05. The BNP values showed significant intragroup and intergroup differences, 6 and 30 days after treatment. The patients from the HSS group reached a better hydration state than the non-HSS group after six days. In addition, the HSS group showed a significant reduction in hospitalization time and readmission rate. CONCLUSIONS: Our data show that the HSS group reached dry weight more rapidly, a significantly faster reduction in BNP levels, shorter hospitalization stay, and lower incidence in readmissions in the 30-day study period.
No takes yet. Share an insight, caveat, or question.
Paterna et al. (2005) conducted an RCT in refractory congestive heart failure (n=94). High-dose furosemide plus hypertonic saline solution vs. Intravenous bolus of furosemide (500 to 1,000 mg twice a day) alone was evaluated on Brain natriuretic peptide (BNP) plasma levels and hydration state (p=<0.05). High-dose furosemide plus hypertonic saline solution significantly increased daily diuresis and natriuresis (p<0.05) and reduced BNP levels and readmissions compared to furosemide alone.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: